Quanterix Corp. announced it has partnered with the Alzheimer’s Drug Discovery Foundation to accelerate the development of a multi-analyte plasma test for early detection of Alzheimer’s disease.
Through the partnership, the Alzheimer’s Drug Discovery Foundation (ADDF) will fund a series of clinical trials to validate the test in collaboration with Amsterdam University Medical Centers.
“We are in a historic moment with plasma-based biomarkers for Alzheimer’s disease detection nearing clinical implementation,” Charlotte E. Teunissen, PhD, professor at Amsterdam